Last reviewed · How we verify
Depression Treatment Adjunct
Approved treatments
- Abilify · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Seroquel · AstraZeneca
- Zyprexa · Eli Lilly
- Abilify · Generic (originally Otsuka/BMS)
Third-generation antipsychotic that acts as a partial agonist at D2 and 5-HT1A receptors, stabilizing dopamine activity rather than simply blocking it. - Seroquel · University of Pittsburgh
- Quetiapin · Sykehuset Innlandet HF
- Zyprexa · Washington University School of Medicine
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Depression Treatment Adjunct patent landscape — cliff calendar, originator estates, attackable patents
- Depression Treatment Adjunct treatment landscape brief
- Depression Treatment Adjunct treatment updates RSS
Frequently asked questions about Depression Treatment Adjunct
What drugs treat Depression Treatment Adjunct?
Tracked treatments include Abilify, Seroquel, Zyprexa, Quetiapin.
What is the treatment for Depression Treatment Adjunct?
Standard treatment for Depression Treatment Adjunct includes Abilify, Seroquel, Zyprexa, Quetiapin. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Depression Treatment Adjunct patent cliff · Depression Treatment Adjunct CI report
- Treatment: Abilify · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Treatment: Seroquel · AstraZeneca
- Treatment: Zyprexa · Eli Lilly
- Treatment: Abilify · Generic (originally Otsuka/BMS)
- Treatment: Seroquel · University of Pittsburgh
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing